Vivimed Labs reschedules board meeting to May 30 for Q4FY26 results

Vivimed Labs Limited has rescheduled its board meeting to approve the audited financial results for the quarter and year ending March 31, 2026. The meeting, originally set for May 28, 2026, will now take place on May 30, 2026, in Hyderabad. This postponement impacts the timeline for the release of the company's Q4FY26 and FY26 standalone and consolidated financial results.

The board will convene to review and approve the audited financial statements for both standalone and consolidated operations. The outcome of this meeting is critical for shareholders as it will determine the company's financial performance for the full fiscal year and the final quarter.

Consequently, the trading window for dealing in the company's securities remains closed for designated persons. This restriction will continue until 48 hours after the declaration of the financial results following the rescheduled meeting on May 30, 2026.

The regulatory filing was submitted to BSE Limited and National Stock Exchange of India Ltd. to inform the exchanges of the change in schedule. The company's BSE code is 532660, and its NSE symbol is VIVIMEDLAB.

Event Details	Information
Original Meeting Date	May 28, 2026
Rescheduled Meeting Date	May 30, 2026
Meeting Location	Hyderabad
Agenda	Audited Financial Results (Standalone & Consolidated) for Q4 and FY ending March 31, 2026
Trading Window Status	Closed until 48 hours post-results declaration

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.19%	+3.23%	-2.33%	-74.74%	-74.74%	+7.52%

Vivimed Labs has informed the stock exchanges of an upcoming Board of Directors meeting scheduled for Thursday, May 28, 2026, to be held at Hyderabad. The intimation, dated May 16, 2026, was filed pursuant to Regulation 29 of the SEBI (Listing Obligations & Disclosure Requirements), 2015.

Board Meeting Agenda

The primary purpose of the meeting is to consider and approve the audited financial results of the company for the quarter and year ending March 31, 2026. The Board will review both standalone and consolidated financial statements, in addition to any other items that may be placed before it.

Key details of the scheduled meeting are summarised below:

Parameter:	Details
Meeting Date:	Thursday, May 28, 2026
Meeting Location:	Hyderabad
Notice Date:	May 16, 2026
Regulatory Compliance:	Regulation 29, SEBI (LODR), 2015
Financial Period Under Review:	Quarter and year ending March 31, 2026
Results Type:	Audited Standalone & Consolidated

Regulatory Compliance

The notice was issued in accordance with Regulation 29 of the SEBI (Listing Obligations & Disclosure Requirements), 2015, which mandates listed companies to provide advance intimation to stock exchanges prior to board meetings where financial results are to be considered. The communication was signed by Yugandhar Kopparthi, Company Secretary of Vivimed Labs.